Skip to content
Screener

Axsome Therapeutics AXSM Q1 2026 earnings

Reported May 4, 2026 · Before market open

Revenue$189.4MMiss by $1.5M
EPS-$1.26Miss by $0.41
Revenue estimate$190.9M
EPS estimate-$0.85

Next report

Nov 2, 2026 (in a month)
Revenue estimate$258.3M
EPS estimate-$0.49

Financials

Q1 2026

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$8.65B+52.0%
Enterprise value$8.56B+52.9%
P/S12.2×-1.0×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity4×+0.1×
Current ratio1.4×-0.6×

Segments

By product

See full
Royalty And Milestone Revenue$1.8M+63.2%
Milestone Revenue$500.0K—
Royalty$500.0K-54.8%

FAQ

When did Axsome Therapeutics report Q1 2026 earnings?
Axsome Therapeutics (AXSM) reported Q1 2026 earnings on May 4, 2026 before market open.
What were Axsome Therapeutics's Q1 2026 revenue and EPS?
Axsome Therapeutics reported revenue of $189.4M and eps of $-1.26 for Q1 2026.
Did Axsome Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $190.9M by $1.5M. EPS missed the consensus estimate of $-0.85 by $0.41.
How did Axsome Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 55.9% from $121.5M a year earlier and eps declined 57.5% from $-0.80.
Where can I find Axsome Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-202506) and the 10-Q periodic report (0001193125-26-204274) directly on SEC EDGAR. The filing index links above go to sec.gov.